Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Insights into HER2 signaling from step-by-step optimization of anti-HER2 antibodies

8 Apr 2014

Abstract excerpt

HER2, a ligand-free tyrosine kinase receptor of the HER family, is frequently overexpressed in breast cancer. The anti-HER2 antibody trastuzumab has shown significant clinical benefits in metastatic breast cancer; however, resistance to trastuzumab is common. The development of monoclonal antibodies that have complementary mechanisms of action results in a more comprehensive blockade of ErbB2 signaling,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glycosylation and Glycoproteins Research
Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24838231
DOI: 10.4161/mabs.28786

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Insights into HER2 signaling from step-by-step optimization of anti-HER2 antibodiesPMID 24838231Read ↗

The Evolving Landscape of HER2 Targeting in Breast Cancer.Semantic proximity Read ↗

HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocksSemantic proximity Read ↗

Molecular Pathways and Mechanisms of HER2 in Cancer TherapySemantic proximity Read ↗

Phage display for discovery of anticancer antibodiesSemantic proximity Read ↗

Binding and functional profiling of antibody mutants guides selection of optimal candidates as antibody drug conjugates.Semantic proximity Read ↗

Structure-guided computational design and mechanistic understanding of the p95HER2-targeting NAZ-mAb antibody and its variantsSemantic proximity Read ↗

Computational Engineering of a Therapeutic Antibody to Inhibit Multiple Mutants of HER2 Without Compromising Inhibition of the Canonical HER2Semantic proximity Read ↗

Evolution of phage display libraries for therapeutic antibody discoverySemantic proximity Read ↗

Effective Optimization of Antibody Affinity by Phage Display Integrated with High-Throughput DNA Synthesis and Sequencing TechnologiesSemantic proximity Read ↗

Thirty Years of HER3: From Basic Biology to Therapeutic InterventionsSemantic proximity Read ↗

Hotspot mutations in HER2 interfaces destabilize structure, causing breast cancer treatment failureSemantic proximity Read ↗

Design, Synthesis, and Docking Studies of Peptidomimetics Based on HER2–Herceptin Binding Site with Potential Antiproliferative Activity Against Breast Cancer Cell linesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.